期刊
CELL CYCLE
卷 9, 期 14, 页码 2764-2768出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/cc.9.14.12267
关键词
miR-34a; CLL; p53; MDM2 SNP309; prognosis; apoptosis
类别
资金
- Klinische Malignom und Zytokinforschung Salzburg-Innsbruck GmbH
- Jubilaumsfond der Osterreichischen Nationalbank [12170, 10990]
- Austrian Science Foundation [P19481-B12, L488-B13]
- SFB program [P021]
- Austrian Science Fund (FWF) [P19481] Funding Source: Austrian Science Fund (FWF)
Chronic lymphocytic leukemia (CLL) has an incidence 4/1,00,000 people in the western world and is one of the first cancers reported to be associated with deregulated miRNA expression. microRNAs are small non coding RNAs that are important regulators of protein expression through binding to their untranslated 3'-UTR region. The miR-34 family was demonstrated to be induced by the tumor suppressor p53 and to elicit p53-like responses like senescence, cell cycle arrest and apoptosis depending on the cell type. We have shown in a recent paper that miR-34a is severely increased in the TCL1-mouse model of CLL. This finding was reflected in human CLL. Moreover, it is demonstrated that its expression is dependent on the presence of the SNP309 in the intronic promoter of the MDM2 gene. In addition, low miR-34a expression was associated with shorter time to treatment (log-rank p = 0.003) in CLL. When reintroduced into CLL cells, miR-34a was able to induce apoptosis. Interestingly, this was dependent on an intact p53 pathway. Here, we present data showing that knockdown of p53 in HCT-116 cells severely reduces miR-34a induced apoptosis. In conclusion, miR-34a is proposed as a marker for the activity of the p53 pathway in CLL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据